Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7246 to 7260 of 7707 results

  1. Systemic juvenile idiopathic arthritis: canakinumab (ESNM36)

    This evidence summary has been withdrawn. An NHS England clinical commissioning policy statement on biologic therapies for the treatment of juvenile idiopathic arthritis is available.

    Evidence summary
    Published
    18 March 2014

  2. Partial seizures in children and young people with epilepsy: zonisamide as adjunctive therapy (ESNM37)

    This evidence summary has been updated and replaced by NICE guideline NG217.

    Evidence summary
    Published
    18 March 2014

  3. Induction of labour: misoprostol vaginal delivery system (ESNM38)

    We withdrew this evidence summary in May 2021 because the manufacturer has discontinued the product.

    Evidence summary
    Published
    25 March 2014

  4. Schizophrenia: aripiprazole prolonged-release suspension for injection (ESNM39)

    This evidence summary has been updated and replaced by the NICE guideline CG178 (published February 2014).

    Evidence summary
    Published
    26 March 2014

  5. Type 2 diabetes: insulin degludec (ESNM4)

    This evidence summary has been updated and replaced by NICE advice ESNM25.

    Evidence summary
    Published
    2 November 2012

  6. Visual impairment due to myopic choroidal neovascularisation: aflibercept (ESNM76)

    This evidence summary has been replaced by NICE technology appraisal guidance 486.  

    Evidence summary
    Published
    14 June 2016

  7. Moderate to severe acute post-operative pain: fentanyl transdermal system (ESNM77)

    This evidence summary was withdrawn in September 2017 as the medicine is no longer available.

    Evidence summary
    Published
    21 June 2016

  8. Pre-exposure prophylaxis of HIV in adults at high risk: Truvada (emtricitabine/tenofovir disoproxil) (ESNM78)

    This advice has been updated and replaced by NICE guideline NG221.

    Evidence summary
    Published
    5 October 2016

  9. Chronic obstructive pulmonary disease: aclidinium bromide (ESNM8)

    This evidence summary has been updated and replaced by NICE guideline 115.

    Evidence summary
    Published
    7 January 2013

  10. Chronic obstructive pulmonary disease: glycopyrronium bromide (ESNM9)

    This evidence summary has been updated and replaced by NICE guideline 115.

    Evidence summary
    Published
    7 January 2013

  11. Significant haemorrhage following trauma: tranexamic acid (ESUOM1)

    This evidence summary has been updated and replaced by NICE guideline NG39.

    Evidence summary
    Published
    16 October 2012

  12. Nocturia and nocturnal polyuria in men with lower urinary tract symptoms: oral desmopressin (ESUOM10)

    This evidence summary has been withdrawn because a product containing oral desmopressin with a marketing authorisation for treating nocturia and nocturnal polyuria in men with lower urinary tract symptom is now available in the UK.

    Evidence summary
    Published
    9 April 2013

  13. Induction of labour in late intrauterine fetal death: vaginal misoprostol (after oral mifepristone) (ESUOM11)

    This evidence summary has been updated and replaced by NICE guideline NG207.

    Evidence summary
    Published
    30 April 2013

  14. Generalised anxiety disorder: quetiapine (ESUOM12)

    This evidence summary has been updated and replaced by NICE guideline CG113 and subsequent surveillance reviews.

    Evidence summary
    Published
    15 May 2013

  15. Adjunctive colposcopy technologies for examination of the uterine cervix – DySIS and the Niris Imaging System (DG4)

    This guidance has been updated and replaced by NICE diagnostics guidance 32.

    Diagnostics guidance
    Published
    1 August 2012